Aim Immunotech INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
AMEX
AIM ImmunoTech's Q2 2026 report shows substantial cash infusion from financing activities and regained NYSE American compliance, while R&D spending decreases.
AMEX
AIM ImmunoTech reported reduced net losses for Q3 and the first nine months of 2025, driven by cost-cutting and a legal fee settlement, despite declining revenue and ongoing liquidity concerns.
AMEX
AIM ImmunoTech reported increased net losses for the quarter, significant cash depletion, and a going concern warning, despite regaining NYSE American listing after a reverse stock split and securing new financing.
AMEX
AIM ImmunoTech reports a decreased net loss for Q1 2025 but faces challenges including a potential delisting from NYSE American and going concern uncertainties.
AMEX
AIM ImmunoTech's Q3 2024 results show a reduced net loss compared to the previous year, alongside ongoing clinical trial advancements and strategic financial maneuvers.
AMEX
AIM ImmunoTech reported a reduced net loss for Q2 2024 compared to Q2 2023, alongside updates on clinical trials and financial activities.
AMEX
AIM ImmunoTech's first quarter 2024 results show an increased net loss compared to the same period last year, alongside ongoing clinical trials and strategic financial moves.